See Outsourcing Pharma’s latest piece on using Real-World Data (RWD) to bridge the evidence gap in medicine. Select excerpts below.
The lack of diversity in clinical trials contributes to widening health disparities and delaying equitable access to medications and treatment. Today, with technologies like Generative Artificial Intelligence (AI), Atropos Health is transforming the process of developing insights from RWD to recreate clinical trials in diverse populations with unparalleled speed and accuracy. We aim to positively impact marginalized populations and drive more inclusive healthcare outcomes.
—
Select quotes from Atropos Health:
Dr. Brigham Hyde, co-founder and CEO of Atropos Health, shared how democratizing access to high-quality evidence and promoting diversity in research, we can work towards achieving health equity and mitigating disparities in healthcare delivery.
“By ensuring that clinical evidence reflects the diversity of patient demographics, we can identify treatment strategies that are most cost effective across different population groups. This, in turn, facilitate more personalized and culturally sensitive care, ultimately leading to better outcomes,” Hyde said. “Additionally, our technology has the capacity to inform the design of more inclusive clinical trials.”
Hyde also took on the evolving landscape of evidence-based medicine and its potential.
“The future of evidence-based medicine holds immense promise, fueled by advances in technology and evolving regulatory frameworks. I foresee a paradigm shift towards a more holistic and patient-centered approach to evidence generation.”
To learn more about how to usher in a new era of evidence-based medicine that prioritizes equity, accessibility and patient empowerment for your organization, contact us today.